United States Patent 6,878,721: Indacaterol Patent Scope, Claims, Expiration and Generic Entry Analysis

U.S. Patent No. 6,878,721 is the principal compound patent covering indacaterol, a long-acting beta2-adrenergic agonist developed by Novartis. The patent claims a broad genus of substituted amino alcohol quinolinone compounds, selected species including indacaterol, pharmaceutical compositions, therapeutic uses, and manufacturing processes. The patent issued April 12, 2005, and its ordinary U.S. patent term expired April 21, 2020, based on the earliest claimed priority date of April 21, 1999.[1]

Indacaterol was approved by the FDA as Arcapta Neohaler in 2011 for long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, or COPD.[2] The patent is no longer a blocking U.S. composition patent, although later patents covering formulations, inhaler devices, salts, crystalline forms, or combination products may have affected commercial competition.

What drug does U.S. Patent 6,878,721 protect?

The patent protects indacaterol and a structurally related class of beta2-adrenergic agonists.

The principal indacaterol structure identified in claim 8 is:

5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one

The marketed active pharmaceutical ingredient is generally administered as indacaterol maleate. The patent claims the active compound in free form and in salt or solvate form, which encompasses pharmaceutically relevant salt forms unless a separate limitation narrows the claim.

Item	Patent-related description
Active ingredient	Indacaterol
Commercial salt	Indacaterol maleate
Pharmacologic class	Long-acting beta2-adrenergic agonist
Primary approved use	Maintenance treatment of COPD
U.S. product	Arcapta Neohaler
FDA approval	July 1, 2011
Patent	U.S. 6,878,721
Patent owner at issuance	Novartis AG
Earliest priority date	April 21, 1999
Issue date	April 12, 2005
Ordinary expiration	April 21, 2020

The claim language also covers structurally related quinolinone compounds with substituted indanyl, tetralin, benzocycloheptene, and fused-ring amino substituents. The patent therefore has value beyond the commercial species, particularly against close analogues that retain the claimed quinolinone-amino alcohol pharmacophore.

What are the independent claims in U.S. Patent 6,878,721?

Claims 1, 9, 11, 12, 14 and 19 are the main independent claim categories.

Claim 1: Broad chemical genus

Claim 1 covers a compound of the stated formula in free, salt, or solvate form. Its principal structural elements include:

A substituted quinolinone-type core.
An amino alcohol side chain.
An aromatic or fused-ring Ar group.
Variable substitution at multiple ring positions.
Optional halogen, alkyl, alkoxy, hydroxy, cyano, carboxy, amide and heteroatom-containing substituents.
R or S configuration at the marked stereocenter when the relevant substituent is hydroxy or alkoxy.
One or two ring nitrogens or carbon atoms in the heteroaromatic portion.
Multiple permissible ring-fusion and heterocyclic alternatives.

This is a Markush claim. Its scope depends on whether a competing molecule satisfies every structural limitation, including the definition of Ar, the substitution pattern, stereochemistry, and the values assigned to X, Y, n, p, q and r.

Claim 8: Enumerated compounds and indacaterol coverage

Claim 8 is materially narrower than claim 1. It identifies specific substitution patterns and separately lists named compounds.

The indacaterol embodiment is the compound with:

A 5,6-diethyl-indan-2-yl amino substituent.
An 8-hydroxy quinolin-2-one core.
A 1-hydroxyethyl side chain.
The relevant R configuration.
Free, salt or solvate form.

The claim also identifies related compounds containing dimethoxy, methyl, methoxymethyl, fused cyclopentyl, benzocycloheptene and other substitutions. A competitor making indacaterol maleate would face direct literal-claim exposure under the compound language, subject to patent-term and claim-validity analysis.

Claims 9, 10 and 15: Pharmaceutical compositions

These claims cover compositions containing a claimed compound with a pharmaceutically acceptable carrier. They extend protection from the active molecule to dosage forms containing the molecule, but they are not limited to a particular inhaler, propellant, excipient, capsule, particle size or device unless those limitations appear in the claim.

Claims 11 through 13 and 19: Method-of-use claims

The method claims cover treatment of:

Chronic or acute urticaria.
Psoriasis.
Allergic conjunctivitis.
Actinitis.
Hay fever.
Mastocytosis.
Obstructive or inflammatory airways disease.
Premature labour pain.

Claims 12 and 13 are the most commercially relevant method claims because they address obstructive or inflammatory airways disease. Claim 13 specifically requires a compound within claim 8.

The approved COPD indication falls within the broad airway-disease language of claims 12 and 13. Method claims, however, do not necessarily block an ANDA that uses a non-infringing label, particularly where the generic label omits or carves out a patented indication. The commercial significance of these claims therefore depends on the FDA label and the product’s intended use.

Claim 14: Manufacturing process

Claim 14 covers processes for preparing the claimed compounds. It includes:

Coupling or reacting protected or unprotected intermediates.
Reduction of a keto group to produce the secondary alcohol.
Reduction of a hydroxy-substituted compound to produce the corresponding hydrogen compound.
O-alkylation to produce alkoxy analogues.
Reaction with alcohols to replace a leaving group.
Deprotection and recovery of the free compound, salt or solvate.

The process claim can create manufacturing risk even where a competitor avoids a compound claim. Its practical value is lower when an alternative synthetic route does not use the claimed reaction sequence or intermediates.

How broad is the chemical scope of claim 1?

Claim 1 is substantially broader than the commercial indacaterol species. It covers a large genus defined by functional substituent variables and ring-system alternatives.

The most important breadth drivers are:

Free compounds, salts and solvates are all included.
The claim permits both R and S configurations, or mixtures, at the specified stereocenter.
Ar can contain multiple substituted aromatic and fused-ring systems.
The quinolinone ring can carry diverse alkyl, alkoxy, hydroxy, halogen, cyano, amide and oxygen-containing substituents.
Several ring positions allow paired substitution patterns or fused carbocyclic and heterocyclic rings.
The claim is not limited to inhaled administration.
The claim is not limited to COPD or any single disease.

This breadth creates potential validity pressure. A Markush claim of this size may face prior-art, written-description, enablement, anticipation and obviousness challenges if the specification does not support the full claimed genus. The narrower species claims, especially claim 8 and the stereochemical claims, are generally more resistant to genus-wide invalidity attacks because they identify particular compounds and substitution patterns.

Which claims specifically cover indacaterol?

The strongest indacaterol-related claims are claims 1, 2, 3, 6, 7, 8, 9, 10, 12, 13, 14 and 15.

Claim	Relevance to indacaterol
1	Broad genus covering the core compound structure
2	Narrows Ar and quinolinone substitution
3	Requires the R configuration
6	Repeats the narrower substituted Ar structure in free, salt or solvate form
7	Requires the R configuration
8	Specifically lists indacaterol and related compounds
9	Composition containing a claim 1 compound
10	Composition containing a claim 7 compound
12	Treatment of obstructive or inflammatory airways disease
13	Treatment of airway disease using a claim 8 compound
14	Preparation processes for the claimed compounds
15	Composition containing a claim 8 compound
17	Narrower 5,6-dialkyl Ar substitution
18	Narrower 5,6-dialkyl Ar substitution with R configuration

Claims 8 and 13 are the clearest commercially relevant claim pair for indacaterol: claim 8 covers the molecule, and claim 13 covers use of the molecule for airway disease.

When did U.S. Patent 6,878,721 lose exclusivity?

The patent’s ordinary term expired April 21, 2020. The calculation follows the 20-year term measured from the earliest effective nonprovisional priority date under the post-1995 U.S. patent-term regime.[1]

Milestone	Date
Earliest claimed priority	April 21, 1999
U.S. application and prosecution period	Patent-specific
Patent issued	April 12, 2005
Ordinary patent expiration	April 21, 2020
FDA approval of Arcapta Neohaler	July 1, 2011
Five-year NCE exclusivity endpoint	Approximately July 1, 2016

No patent-term extension appears to have extended U.S. Patent 6,878,721 beyond April 21, 2020. FDA regulatory exclusivity and patent exclusivity were separate rights. The five-year new chemical entity exclusivity period barred submission of an ANDA containing a paragraph IV certification during the applicable period, but it did not extend the patent term.[2][3]

What was the Orange Book status of indacaterol?

Arcapta Neohaler was listed in the FDA Orange Book under NDA 022383. The product contained indacaterol maleate and used the Neohaler inhalation device.[3]

The Orange Book listing identified U.S. Patent 6,878,721 as a drug-substance or product-related patent associated with indacaterol. The patent’s expiration in 2020 removed the primary listed compound patent from the blocking period. Orange Book status does not itself establish infringement, validity or enforceability. It records patents submitted by the NDA holder and accepted for listing under FDA procedures.

FDA approval was for once-daily maintenance treatment of airflow obstruction in patients with COPD. The label did not approve indacaterol as a rescue medication and warned against use for acute bronchospasm.[2]

Were there Paragraph IV challenges to U.S. Patent 6,878,721?

A Paragraph IV certification would have been the principal ANDA pathway for challenging an unexpired listed patent. Public FDA product and Orange Book records do not establish a reported, commercially material Paragraph IV litigation campaign directed specifically at U.S. Patent 6,878,721.

The practical reason is timing. The patent expired in April 2020, while the product had already faced commercial limitations in the U.S. market. Once the patent expired, an ANDA applicant no longer needed to rely on a Paragraph IV challenge to enter against the compound patent. A post-expiration ANDA could use a paragraph II or paragraph III position depending on the status of other listed patents and regulatory requirements.[3]

The absence of a reported challenge does not establish that the claims were invulnerable. It indicates that the commercial opportunity for a litigation-driven early launch was limited.

What later patents could affect indacaterol generic entry?

The primary patent risk shifted from the active compound to secondary patent categories.

Formulation patents

Potential formulation rights may cover:

Indacaterol maleate particle properties.
Dry-powder inhalation compositions.
Carrier particles such as lactose.
Dose uniformity and aerodynamic performance.
Capsule-based inhalation dosage forms.
Specific ratios of active ingredient to carrier.
Stabilization or moisture-control systems.

A formulation patent does not necessarily block all generic indacaterol products. Its effect depends on whether the proposed ANDA formulation practices the claimed composition or performance parameters.

Device and delivery patents

The Neohaler platform may be protected by separate device patents covering:

Capsule piercing.
Airflow channels.
Dose loading.
Mouthpiece geometry.
Rotational or sliding components.
Powder deaggregation.

A generic applicant may avoid device patents by using a different inhaler, although device substitution can create FDA equivalence and human-factors issues.

Combination-product patents

Indacaterol has been combined outside the United States and in development programs with agents such as glycopyrronium, umeclidinium or mometasone. Combination products can create separate patent exposure involving:

Fixed-dose combinations.
Specific dose ratios.
Treatment of COPD or asthma.
Dual or triple inhaler systems.
Co-formulated dry powders.

These patents are distinct from the expired compound claim in U.S. 6,878,721.

Salt, crystal and solid-form patents

Indacaterol maleate, alternative salts, solvates and crystalline forms may be subject to separate patents. A salt or solid-form patent can remain relevant after a broad compound patent expires, but its scope is narrower and depends on the exact solid form used by the generic applicant.

How strong is the patent estate for indacaterol?

The estate was strongest before 2020 because U.S. 6,878,721 combined broad genus claims with specific species, composition claims and airway-use claims. Its strongest enforcement position was against a product containing indacaterol itself.

The estate is weaker after expiration because:

The principal compound patent is no longer in force.
A generic can avoid expired method claims through labeling or indication carve-outs.
Process claims can be bypassed with a different synthesis.
Formulation and device patents usually cover narrower implementation details.
FDA approval of an inhaled generic depends on product-specific regulatory requirements rather than the expired compound patent.

Estate component	Historical strength	Post-2020 significance
Broad chemical genus	High	Expired
Indacaterol species	Very high	Expired
R-configured compound	High	Expired
COPD and airway methods	Moderate to high	Expired or label-dependent
Manufacturing process	Moderate	Depends on route used
Inhaled formulation	Potentially high	Claim-specific
Inhaler device	Potentially high	Device-specific
Combination products	Product-specific	May remain relevant
Salt and crystal forms	Product-specific	May remain relevant

What generic entry risks exist for indacaterol?

The principal entry scenarios are:

Scenario 1: Single-agent generic after compound-patent expiration

A manufacturer launches an indacaterol inhalation product after addressing FDA bioequivalence, device compatibility and any remaining listed patents. This is the lowest patent-risk scenario if no enforceable secondary patent covers the selected formulation or device.

Scenario 2: Generic with a different inhaler

The applicant uses the same active ingredient but a non-Neohaler device. Patent risk shifts from the active compound to device equivalence, dose delivery and inhaler-specific claims.

Scenario 3: Label-carved generic

The applicant removes indications potentially covered by surviving method-of-use patents. This approach is common where a patent claims a particular disease or patient population rather than the molecule itself.

Scenario 4: Authorized generic or licensed product

The originator or a licensee supplies a lower-priced version. This can reduce litigation but also limits independent generic-market access.

Scenario 5: Combination-product entry

A generic for an indacaterol combination product faces a separate patent landscape. The expired 6,878,721 patent would not by itself authorize a combination product that practices later combination, formulation or device claims.

Which companies challenged or competed with indacaterol?

The competitive landscape has included long-acting bronchodilators from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis and other inhaled-drug manufacturers.

Product	Active ingredient	Company	Class
Arcapta Neohaler	Indacaterol	Novartis	LABA
Onbrez Breezhaler	Indacaterol	Novartis	LABA
Striverdi Respimat	Olodaterol	Boehringer Ingelheim	LABA
Serevent	Salmeterol	GlaxoSmithKline	LABA
Foradil	Formoterol	Novartis	LABA
Anoro Ellipta	Umeclidinium/vilanterol	GlaxoSmithKline	LAMA/LABA
Stiolto Respimat	Tiotropium/olodaterol	Boehringer Ingelheim	LAMA/LABA
Ultibro Breezhaler	Indacaterol/glycopyrronium	Novartis	LAMA/LABA

The closest competition came from once-daily LABAs and fixed-dose LAMA/LABA combinations. Competitive pressure reduced the commercial value of an indacaterol-only product even before compound-patent expiration.

What was the revenue exposure associated with the patent?

The patent protected a product in a large COPD market but did not create exclusive control over all LABA therapy. Arcapta was one of several maintenance inhalers and faced competition from established twice-daily and once-daily products.

The patent’s commercial value was concentrated in:

Indacaterol monotherapy.
Indacaterol-containing combination products.
Foreign markets with later patent expiry.
Licensing and cross-border commercialization of Breezhaler products.
Follow-on products using the same active ingredient with different combinations or devices.

U.S. revenue exposure was constrained by the product’s limited market position and by competition from LAMA/LABA combinations. Global exposure was broader because indacaterol was commercialized under Onbrez Breezhaler and in combination products in multiple jurisdictions.[2][4]

What geographic coverage did the indacaterol patent family have?

The invention was pursued internationally through a priority filing and corresponding patent applications in major pharmaceutical markets. The commercial family included protection or applications in jurisdictions such as the United States and Europe, with additional national filings in other markets.

Expiration was jurisdiction-specific. The U.S. date of April 21, 2020 should not be applied automatically to Europe, Canada, Japan, Australia or emerging markets. Patent-term adjustments, supplementary protection certificates, pediatric extensions, prosecution history and national maintenance requirements can produce different dates.

For freedom-to-operate analysis, the relevant questions are:

Whether the jurisdiction granted the indacaterol species.
Whether the granted claim covers the marketed salt.
Whether a supplementary protection certificate or patent-term extension applied.
Whether later formulation or device patents remained in force.
Whether local regulatory linkage rules delay generic approval.

Key Takeaways

U.S. Patent 6,878,721 is the core indacaterol compound patent.
Claim 1 covers a broad genus of substituted quinolinone amino alcohols.
Claim 8 specifically identifies indacaterol and closely related compounds.
Claims 9, 10 and 15 cover pharmaceutical compositions.
Claims 12 and 13 cover treatment of obstructive or inflammatory airway disease.
Claim 14 covers several synthetic routes and intermediate transformations.
The ordinary U.S. patent term expired April 21, 2020.
The patent is no longer a U.S. blocking compound patent.
Remaining commercial risk is concentrated in formulation, inhaler-device, salt, solid-form and combination-product patents.
FDA approval of Arcapta Neohaler occurred July 1, 2011 under NDA 022383.
Generic entry after expiration depends primarily on FDA product requirements and any surviving secondary patents.

FAQs About U.S. Patent 6,878,721 and Indacaterol

Is indacaterol protected by U.S. Patent 6,878,721?

Yes. Claim 8 expressly lists indacaterol, while claims 1, 3, 7, 13 and related composition claims provide broader or complementary coverage.

Did U.S. Patent 6,878,721 cover indacaterol maleate?

Yes. The claims expressly include compounds in free, salt or solvate form, which encompasses the maleate salt used in commercial products, subject to claim construction.

Can a generic launch indacaterol after April 21, 2020?

The expired compound patent no longer prevents launch. A generic must still address FDA approval requirements and any enforceable patents covering the proposed inhaler, formulation, salt, solid form or combination product.

Did the patent cover indacaterol inhalers?

The patent covers pharmaceutical compositions but does not, based on the supplied claims, require a particular inhaler device or capsule-delivery mechanism. Separate device or formulation patents may provide narrower protection.

Does claim 13 cover all COPD treatment with indacaterol?

Claim 13 covers treatment of obstructive or inflammatory airway disease using a compound within claim 8. Its enforcement scope depends on the claim construction, the product label, the prescribed use and the status of the patent. That claim expired with the patent term.

References

United States Patent and Trademark Office. (2005). U.S. Patent No. 6,878,721, Novel compounds. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2011). Arcapta Neohaler prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
Novartis Pharmaceuticals Corporation. (2011). Arcapta Neohaler: FDA approval materials and prescribing information.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9913083	Jun 04, 1999

PCT Information
PCT Filed	June 02, 2000	PCT Application Number:	PCT/EP00/05058
PCT Publication Date:	December 14, 2000	PCT Publication Number:	WO00/75114

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1183240	⤷ Start Trial	C300437	Netherlands	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	CA 2010 00006	Denmark	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	91651	Luxembourg	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	SPC009/2010	Ireland	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	10C0006	France	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	SPC/GB10/009	United Kingdom	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 6,878,721